Date: 2014-07-01
Type of information: Nomination
Compound: president
Company: Onkaido Therapeutics, Moderna Therapeutics' company (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 1, 2014, Moderna Therapeutics announced that Stephen Kelsey will become president of Onkaido Therapeutics, Moderna’s oncology drug development company, effective July 21. Launched in January of this year, Onkaido is Moderna’s first venture company, focused exclusively on developing and commercializing mRNA-based oncology treatments.
- Dr. Kelsey has extensive pharmaceutical industry experience in oncology. After 16 years as an academic clinician, he started his industry career at Sugen, and later was vice president of hematology/oncology at Genentech. While at Genentech, Dr. Kelsey played a significant role in the development of key products Perjeta®, Kadcyla® and Erivedge®, as well as other molecules in the company’s oncology portfolio. He left Genentech in 2009 to run Geron’s oncology division, where he served for four years as executive vice president, research and development, and chief medical officer helping to develop therapeutics and vaccines to fight cancer. Most recently Dr. Kelsey was senior vice president, new projects at the cancer therapies company Medivation. Dr. Kelsey graduated with a Doctorate of Medicine from the University of Birmingham, UK and is a fellow of both the Royal Colleges of Physicians and Pathologists, UK. For his new role as President of Onkaido, Dr. Kelsey will relocate to Cambridge from San Francisco.
Financial terms:
Latest news:
Is general: Yes
